TrialPath
Recruiting

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

NCT00131014 · Dana-Farber Cancer Institute
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies
About this study
* Patients who participate will be asked to complete detailed family and medical history questionnaires initially, with a follow-up questionnaire every year. * Patients will be asked to supply a blood sample and possibly a mouthwash sample, both of which can be done by mail. * Patients will be asked to consent to the release of their lymphoma tissue block for the purposes of the study. * Patients will be given letters of invitation for their affected relatives to invite them to participate.
Eligibility criteria
Inclusion Criteria: * Any individual diagnosed with non-Hodgkin's lymphoma or Hodgkin's disease or chronic lymphocytic leukemia (CLL), who has a 1st degree relative (parent, sibling or child) with a lymphoproliferative disorder; or families in which the individual has a lymphoproliferative disorder, and an unusual clustering of frequent or premature solid tumors is also observed. * Family members of the individual, either affected or unaffected with lymphoma, who are contacted by the individual and agree to participate in the study. * Deceased family members may be included in the study. Public records such as death certificates may be used to confirm the history. Consent for medical records or tissue blocks will be obtained from the deceased family member's next of kin. The hierarchy of relatives defined as next of kin is spouse, offspring, parents and siblings. Archived tissue samples may be used for genetic research. * Age \> 18 years Exclusion Criteria: * Subjects without a family history of lymphoma
Study design
Enrollment target: 1500 participants
Age groups: adult, older_adult
Timeline
Starts: 2004-08-09
Estimated completion: 2033-01
Last updated: 2026-04-24
Primary outcomes
  • Genetic factors that contribute to the development of lymphomas and CLL (Indefinite)
Sponsor
Dana-Farber Cancer Institute · other
Contacts & investigators
ContactCeleste Carey, MS · contact · celeste_carey@dfci.harvard.edu · 857-215-1646
ContactJennifer Brown, MD PhD · contact · Jennifer_Brown@dfci.harvard.edu · 617-632-4564
InvestigatorJennifer R. Brown, MD, PhD · principal_investigator, Dana-Farber Cancer Institute
All locations (1)
Dana-Farber Cancer InstituteRecruiting
Boston, Massachusetts, United States
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies · TrialPath